Quell takes new Treg into clinic after transplant study halt Quell Therapeutics changes tack, starting trials of a CAR-Treg in rheumatoid arthritis and systemic sclerosis and sidelining its transplant therapy.

UK biotech #QuellTherapeutics has started #humantrials of #autologousCARTreg therapy QEL-005 in #rheumatoidarthritis and #systemicsclerosis, after pressing pause on its former lead programme for organ transplant rejection.